0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

Large Acquired Nevus or Dysplastic Nevus What’s in the Name of a Nevus?

Rainer Hofmann-Wellenhof, MD1; Ashfaq A. Marghoob, MD2; Iris Zalaudek, MD1
[+] Author Affiliations
1Department of Dermatology, Medical University Graz, Graz, Austria
2Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Dermatol. 2016;152(6):623-624. doi:10.1001/jamadermatol.2015.6186.
Text Size: A A A
Published online

Extract

This Viewpoint discusses use of the term large acquired nevus vs dysplastic nevus.

In 1978, Clark et al1 described a melanoma-prone family with many nevi. The nevi in these family members were variable in size, shape, and color, and many of the nevi had relatively large diameters. In addition, the family members with such nevi were at increased risk of developing melanoma. To help differentiate these nevi from others, Clark et al1 coined the term B-K mole, which later became known as dysplastic nevus (DN).2 Although Clark et al1 did not consider DNs to be obligate precursors to melanoma, they hypothesized that DNs may represent an intermediate-stage lesion with a higher propensity for progression toward melanoma. It is understandable how the aforementioned observation and premise evolved in the minds of many physicians into 2 action items. First, by screening these individuals, one may find de novo melanomas early (which has been reported in various studies3,4). Second, by removing their DNs, one could potentially prevent the development of melanoma. At face value, this premise seemed logical, but, unfortunately, numerous studies3,5 have found that the removal of DNs cannot actually prevent the development of malignant melanoma because most develop de novo. In addition, although 30% of melanomas are histopathologically associated with a nevus, the most common associated nevus is a so-called common or congenital-type nevus.5 Because of the connotations associated with the word dysplastic, alternative names, such as atypical nevus, Clark nevus, and nevus with architectural atypia, had been proposed. However, renaming this nevus did not eradicate the underlying basic conceptual error that had permeated the minds of many physicians that these nevi were histologically and clinically dysplastic and atypical—and, as a consequence, premalignant. Although evidence is emerging that, on a molecular level, there is progressive accumulation of mutations from nevus to melanoma, this does not mean there are clinical or histopathologic features that can reliably identify an intermediate-stage lesion with a heightened risk of transforming into a malignant tumor.4 With the exception of congenital nevi, to our knowledge, no evidence has yet emerged identifying a clinically distinct subset of nevi bearing a higher risk of developing an associated melanoma or transforming into melanoma. Despite this evidence, DNs still cause concern among pathologists, other physicians, and even patients. Physicians often explain to patients that the biopsied nevus was a premelanoma, almost a melanoma, or on its way to becoming a melanoma. Because of this practice, both the physician and patient will often decide to reexcise these nevi to ensure complete removal.

Figures in this Article

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.
Example of a Large Acquired Nevus
Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

673 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Original Article: A Primer on the Precision and Accuracy of the Clinical Examination

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
The Characteristics of the Accuracy of Diagnostic Tests

brightcove.createExperiences();